Pancreatic Acinar Cell Carcinoma Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0040329 (Pancreatic Acinar Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsTreatment